Prophylaxis and treatment of NSAID-induced gastropathy

American Family Physician

Volumn 55, Issue 4, 1997, Pages 1323-1332

  Ament, Paul W ^a   Steven Childers, R ^a  

^a Latrobe Area Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; SUCRALFATE;

CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; DUODENUM ULCER; GASTROINTESTINAL SYMPTOM; HUMAN; PROPHYLAXIS; REVIEW; STOMACH DISEASE; STOMACH MUCOSA; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTRIC MUCOSA; HUMANS; RISK FACTORS; STOMACH DISEASES;

EID: 1842415407     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med 1994;96:274-81.
2. Personal communication with Mark Pavao, Marketing and Research Department, SmithKline Beecham Pharmaceuticals. September 20, 1995.
3. Scheiman JM. NSAID-induced peptic ulcer disease: a critical review of pathogenesis and management. Dig Dis 1994;12:210-22.
4. Lee M. Prevention and treatment of nonsteroidal anti-inflammatory drug-induced gastropathy. South Med J 1995;88:507-13.
5. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A metaanalysis. Ann Intern Med 1991;115:787-96.
6. Scheiman JM, Behler EM, Loeffler KM, Elta GH. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994;39:97-103.
7. Clearfield HR. Management of NSAID-induced ulcer disease. Am Fam Physician 1992;45:255-8.
8. Zfass AM, McHenry L Jr, Sanyal AJ. Nonsteroidal antiinflammatory drug-induced gastroduodenal lesions: prophylaxis and treatment. Gastroenterologist 1993;1:165-9.
9. Heigh RI. Use of NSAIDs. An assault on the upper gastrointestinal tract. Postgrad Med 1994;96(6):63-8.
10. Scarpignato C. Nonsteroidal anti-inflammatory drugs: how do they damage gastroduodenal mucosa? Dig Dis 1995;13(Suppl 1):9-39.
11. McCarthy DM. Mechanisms of mucosal injury and healing: the role of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl 1995;208:24-9.
12. Shorrock CJ, Langman MJ. Nonsteroidal antiinflammatory drug-induced gastric damage: epidemiology. Dig Dis 1995;13(Suppl 1):3-8.
13. Miller DR. Treatment of nonsteroidal anti-inflammatory drug-induced gastropathy. Clin Pharm 1992;11:690-704.
14. Olivero JJ, Graham DY. Gastric adaptation to nonsteroidal anti-inflammatory drugs in man. Scand J Gastroenterol Suppl 1992;193:53-8.
15. Pipkin G, Mills JG. Treatment of nonsteroidal antiinflammatory drug-associated gastric and duodenal damage. Efficacy of antisecretory drugs and mucosal protective compounds. Dig Dis 1995;13(Suppl 1):75-88.
16. Tana AS, Dahill S, Sturrock RD, Lee FD, Russell RI. Predicting NSAID related ulcers - assessment of clinical and pathological risk factors and importance of differences in NSAID. Gut 1994;35:891-5.
17. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991;325:87-91.
18. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988;2(8623):1277-80.
19. Graham DY, White RH, Moreland LW, Schubert IT, Katz R, Jaszewski R, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993;119:257-62.
20. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
21. Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123:344-50.
22. Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol 1996;91(2):223-7.
23. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 1996;334:1435-9.
24. Wallace JL. The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage - potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol 1994;72:1493-8.
25. Roth SH, Tindall EA, Jain AK, McMahon FG, April PA, Bockow BI, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153:2565-71.
26. Roth SH, Bennett R, Caldron P, Mitchell C, Swenson C, Koepp R. A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol 1994;21:1118-23.
27. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol 1993;88:1318-23.
28. Bianchi Porro G, Caruso I, et al. A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients. J Intern Med 1991;229:5-8.
29. Taha AS, McLaughlin S, Sturrock RD, et al. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br J Rheumatol 1989;28:329-32.
30. Cryer B, Feldman M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal anti-inflammatory drug-induced damage. Arch Intern Med 1992;152:1145-55.
31. Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 1993;15:314-20.
32. Caldwell JR, Roth SH. A double blind study comparing the efficacy and safety of enteric coated naproxen to naproxen in the management of NSAID intolerant patients with rheumatoid arthritis and osteoarthritis. Naproxen EC Study Group. J Rheumatol 1994;21:689-95.
33. Cryer B, Feldman M. Strategies for preventing NSAID-induced ulcers. Drug Therapy 1994;24:25-32.
34. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995;38:5-18.